Magnetic resonance imaging (MRI) to study striatal iron accumulation in a rat model of Parkinson's disease.
Abnormal accumulation of iron is observed in neurodegenerative disorders. In Parkinson's disease, an excess of iron has been demonstrated in different structures of the basal ganglia and is suggested to be involved in the pathogenesis of the disease. Using the 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease, the edematous effect of 6-OHDA and its relation with striatal iron accumulation was examined utilizing in vivo magnetic resonance imaging (MRI). The results revealed that in comparison with control animals, injection of 6-OHDA into the rat striatum provoked an edematous process, visible in T2-weighted images that was accompanied by an accumulation of iron clearly detectable in T2*-weighted images. Furthermore, Prussian blue staining to detect iron in sectioned brains confirmed the existence of accumulated iron in the areas of T2* hypointensities. The presence of ED1-positive microglia in the lesioned striatum overlapped with this accumulation of iron, indicating areas of toxicity and loss of dopamine nerve fibers. Correlation analyses demonstrated a direct relation between the hyperintensities caused by the edema and the hypointensities caused by the accumulation of iron.
Department of Integrative Medical Biology, Umeå University, Umeå, Sweden.
Ana
A
Virel
Department of Integrative Medical Biology, Umeå University, Umeå, Sweden.
Erik
E
Faergemann
Department of Radiation Sciences, Umeå University, Umeå, Sweden.
Greger
G
Orädd
Department of Integrative Medical Biology, Umeå University, Umeå, Sweden.
Ingrid
I
Strömberg
D018663:Adrenergic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D003342:Corpus Striatum / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D007150:Immunohistochemistry; D007501:Iron / Q000378:metabolism*; D008279:Magnetic Resonance Imaging; D016627:Oxidopamine / Q000494:pharmacology / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D011859:Radiography; D051381:Rats; D017207:Rats, Sprague-Dawley
D018663:Adrenergic Agents; D016627:Oxidopamine; D007501:Iron